Gilead and Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly HIV Treatment
Go back to Gilead and Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly HIV Treatment| Gilead Sciences (NASDAQ: GILD) | Delayed: 135.77 +2.71 (2.04%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $133.06 | 52 Week High | $108.63 | |||
| Open | $132.68 | 52 Week Low | $71.39 | |||
| Day High | $136.85 | P/E | 75.01 | |||
| Day Low | $132.01 | EPS | $1.81 | |||
| Volume | 5,493,802 | |||||
| Merck & Co. (NYSE: MRK) | Delayed: 130.42 -0.5 (0.38%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $130.92 | 52 Week High | $65.46 | |||
| Open | $129.93 | 52 Week Low | $47.97 | |||
| Day High | $132.84 | P/E | 88.72 | |||
| Day Low | $129.70 | EPS | $1.47 | |||
| Volume | 6,343,840 | |||||
